Futura Medical plc is a pharmaceutical group that develops innovative products for the consumer healthcare market.
Our business strategy is centered on selecting and developing products with regard to five key criteria:
- Return on Investment: we focus on consumer healthcare products that offer the potential for a significant return on the costs of development.
- Product Profile: we focus on topically applied medicines, either stand-alone or in combination with a medical device. We only incorporate existing chemical entities into our products which gives our development activities a lower risk profile.
- Over The Counter ("OTC"): our aim is to produce safe and effective OTC products made available to consumers on a general retail basis or through chemists without the need for a doctor's prescription.
- Strong Intellectual Property: the products are underpinned by our developing and retaining valuable intellectual property including know-how, patents and trademarks to protect their commercial position.
- Licensing: we aim to out-license our products during their development to established pharmaceutical and healthcare groups which offer the best potential commercial opportunities.
The Group's activities have been funded by a combination of share issues, research and development tax credits, interest and government grants. As at 31 December 2009, share issues totalled £16.84 million net of costs. As at 31 December 2009, other funding sources have contributed a further £2.50 million.